Citation

Hosanagar A, Schmale A, LeBlanc A. J. Affect. Disord. 2021; 282: 252-254.

Copyright

(Copyright © 2021, Elsevier Publishing)

DOI

10.1016/j.jad.2020.12.120

PMID

33418374

Abstract

Ketamine's rapid antisuicidal action has gathered significant clinical interest in treatment of depression though concerns exist that its actions occur through the Opioid pathway. A recent study additionally reported that Naltrexone blocks antisuicidal effects of Ketamine suggesting that its antisuicidal effects are also due to opioid mechanisms. We present a case of treatment refractory depression with recent suicide attempt and active suicidal ideations who was on an Opioid partial agonist, Buprenorphine, for management of pain. Patient responded to a trial of IV ketamine treatment with rapid improvement in suicidal thoughts. Patient's suicidal ideations decreased after first Ketamine treatment and resolved after second treatment while maintained on Buprenorphine. Our finding shows that Buprenorphine does not block Ketamine's effects on suicidal ideations and therefore Ketamine treatment could be provided safely in controlled environment to those with substance use disorders or with chronic pain while being maintained on Buprenorphine. Additionally, our case suggests that non-Opioid mechanisms may be involved in Ketamine's antidepressant effects and its response to suicidal ideations in those on Opioid partial agonists.

Language: en

Keywords

Humans; Suicide; Suicidal Ideation; Antidepressive Agents; Ketamine; Antidepressant; Buprenorphine; Depressive Disorder, Treatment-Resistant; Antisuicidal; TRD